The day after announcing it had ended development of its lead candidate revusiran due to an imbalance of deaths in a Phase III trial, Alnylam Pharmaceuticals Inc. took a serious hit on its stock price, but also got reassurance that a broad array of market analysts had determined that because revusiran was substantially differentiated from the rest of Alnylam's RNA-interference pipeline, there probably would be no read-through to the larger portfolio.
Several other publicly traded companies working in the RNA space also saw their share prices decline Oct. 6, but much less so than the 48% shellacking Alnylam shares took (falling from $70.30 to $36.22) by the end of the trading day. Among those other companies, Regulus Therapeutics Inc. was down 5% on the day to $3.36 per share, Dicerna Pharmaceuticals Inc. dropped 14% to $4
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
